FDA Approves Geron’s First Commercial Drug, Competes With Bristol Myers Squibb’s Blood Cancer Drug On Thursday, the FDA approved Geron Corporation’s (NASDAQ:GERN) Rytelo (imetelstat) for adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. The approval covers patients requiring four or more red blood cell units over eight weeks who have not […]